Skip to main content
SpringerLink
Log in

Cardiovascular AEs with immune checkpoint inhibitors

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Amiri-Kordestani L, et al. Cardiovascular adverse events in immune checkpoint inhibitor clinical trials: A U.S. Food and Drug Administration pooled analysis. 54th Annual Meeting of the American Society of Clinical Oncology : abstr. 3009, 1 Jun 2018. Available from: URL: http://abstracts.asco.org/214/AbstView_214_220239.html

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cardiovascular AEs with immune checkpoint inhibitors. Reactions Weekly 1708, 5 (2018). https://doi.org/10.1007/s40278-018-48098-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-018-48098-9

Search

Navigation